Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

CPX-351 is a feasible bridge to allogeneic hematopoietic stem cell transplantation in TP53 mutated acute myeloid leukemia with  myelodisplastic related changes or therapy related without del(17p): Sub-analysis from a large italian real world retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

ILIvana LotesoriereFLFederico LussanaCPCristina Papayannidis

Discussion

Loading...

Member takes

Overview

Observational analysis reveals TP53 mutations pose a prognostic challenge in acute myeloid leukemia, implicating allogeneic stem cell transplantation outcomes.

Key Points

  • TP53 mutations were found to influence the likelihood of complete remission in patients with acute myeloid leukemia.
  • Next Generation Sequencing identified various mutations, highlighting their complex nature among patients.
  • Analysis showed that allogeneic stem cell transplantation may be impacted negatively by the presence of certain mutations.
  • Prognostic impact analysis emphasized the need for careful evaluation of molecular characteristics in treatment decisions.

Cite This Study

Lotesoriere et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d39dhttps://doi.org/10.1182/blood-2025-4608
View Full Paper
Ask AI
Bookmark
Share